Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Sequana Medical AG Stories

2012-10-30 07:26:44

ZÃœRICH, Switzerland, October 30, 2012 /PRNewswire/ -- Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump(R) system in patients with ascites caused by cancer (malignant ascites). The alfapump(R) system was first introduced to the European market last year for patients with refractory ascites caused by advanced liver disease. The system is fully implantable, and automatically and continually collects ascites from the...

2012-03-01 00:00:00

ZÃœRICH, March 1, 2012 /PRNewswire/ -- NUB Grants Approval for Fifteen Leading Hepatology Centres in Germany. Sequana Medical announced today that its ALFApump(R) System has received German Neue Untersuchungs und Behandlungsmethode (NUB) approval which allows participating hospitals to receive reimbursement for innovative new products. Sequana Medical's ALFApump System is a fully implantable pump system designed to remove excess abdominal fluid, known as...

2011-12-09 00:00:00

ZURICH, December 9, 2011 /PRNewswire/ -- NHS National Innovation Centre supports the cost effectiveness of Sequana Medical's ALFApump System Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System commissioned by the National Innovation Centre, the NHS organization which supports innovators, commissioners, and clinicians to speed up the development and use of innovations that will benefit the NHS. Brian Winn, Head...

2011-11-04 05:38:00

ZURICH, Switzerland, November 4, 2011 /PRNewswire/ -- Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis. Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ALFApump System were performed at Vienna General Hospital in October, under the supervision of Univ. Prof. Dr. Markus...

2011-07-13 00:00:00

ZURICH, Switzerland, July 13, 2011 /PRNewswire/ -- New Technology Expands Treatment Options for Patient With Refractory Ascites Due to Liver Cirrhosis. Dr. Farzana Malik Joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump(TM) System. Over the coming months, the company will launch the product in selected hepatology and liver transplant hospitals across...

2011-05-30 00:00:00

ZUG, Switzerland, May 30, 2011 /PRNewswire/ -- NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG ( http://www.sequanamedical.com) as it prepares for the upcoming launch of the ALFApump(TM) System in Europe. "There were a number of compelling reasons to rebrand NovaShunt," commented Noel Johnson, CEO. "We felt the name 'NovaShunt'...